Cancer misinformation (i.e., false, inaccurate or incomplete information) on social media will be examined with a special focus on adolescent and young adult cancer patients and their caregivers. Given the high use of social media by these cancer patients and their caregivers, cancer misinformation may influence their beliefs and attitudes in potentially serious ways. Making decisions based on misinformation could lead to poor health outcomes and decreased survival.
UA botanical researchers are aiming to improve management options for women diagnosed with breast cancer by understanding the safety and potential benefits of over the counter supplements. As part of this effort, we are reaching out to women who have been diagnosed with breast cancer to find out more about the supplements that they may already be using. To participate, a short (5 minute) anonymous survey is available online (see link).
For patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL), treatment options have been limited and prognosis unfavorable. With the recent approval of BLINCYTO® (blinatumomab) in the US, it is important to understand its “real-world” utilization and to assess and understand its effectiveness and safety when administered in clinical practice. This
This is a Phase 1, single center, prospective, randomized, double-blind, placebo-controlled study assessing the effects of chlorine dioxide oral rinse versus placebo on incidence, time to onset, duration, and patient reported outcomes on radiation therapy related OM, RT interruption, and changes in oral microbiome and cytokine composition.
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).
This is a non-interventional, observational study. Multiple myeloma will be treated as per standard therapy and/or with medicinal product prescribed by the treating healthcare provider based upon his/her clinical judgment.